**Supplementary Table 1.** Propensity score analysis: reduction in weight and glycosylated hemoglobin (HbA1c) after 6 months of treatment†.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Outcome** | **Sitagliptin** | **n** | **Dapagliflozin** | **n** | **Dapa-Sita‡** |
| Weight reduction§ | 37.0% | 54 | 64.8% | 54 | **27.8%** |
| HbA1c reduction¶ | 29.1% | 55 | 30.9% | 55 | 1.8% |
| Weight + HbA1c reduction | 53.7% | 54 | 77.8% | 54 | **24.1%** |
| †Statistically significant differences are marked in bold. ‡“Dapa-Sita” was calculated as follows: % in dapagliflozin cohort - % in sitagliptin cohort. §Weight reduction was defined as a reduction of ≥ 1.5 kg after 6 months of treatment.¶HbA1c reduction was defined as a reduction of ≥ 0.5% after 6 months of treatment. |